Guangdong Zhongsheng Pharmaceutical Co., Ltd.

SZSE:002317 Stock Report

Market Cap: CN¥10.2b

Guangdong Zhongsheng Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

Guangdong Zhongsheng Pharmaceutical has a total shareholder equity of CN¥4.5B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥5.8B and CN¥1.3B respectively. Guangdong Zhongsheng Pharmaceutical's EBIT is CN¥213.7M making its interest coverage ratio -10.8. It has cash and short-term investments of CN¥1.5B.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ratio-10.8x
CashCN¥1.54b
EquityCN¥4.54b
Total liabilitiesCN¥1.28b
Total assetsCN¥5.82b

Recent financial health updates

These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Jul 12
These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Mar 18
Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Recent updates

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Nov 04
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Investor Optimism Abounds Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) But Growth Is Lacking

Oct 07
Investor Optimism Abounds Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) But Growth Is Lacking

These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Jul 12
These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Jun 18
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

May 20
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Apr 29
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Mar 18
Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Feb 29
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Financial Position Analysis

Short Term Liabilities: 002317's short term assets (CN¥3.3B) exceed its short term liabilities (CN¥418.3M).

Long Term Liabilities: 002317's short term assets (CN¥3.3B) exceed its long term liabilities (CN¥858.6M).

Debt to Equity History and Analysis

Debt Level: 002317 is debt free.

Reducing Debt: 002317 has no debt compared to 5 years ago when its debt to equity ratio was 18.5%.

Debt Coverage: 002317 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 002317 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 02:23
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Zhongsheng Pharmaceutical Co., Ltd. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
Shanshan LiChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)